who should avoid glp-1 medications Part 1 of a 3-Part Series; for Weight Loss GLP-1 Safety: Who Should Avoid

Losing 40 to 60 pounds over several months changes how you look in ways that your brain may struggle to process

Oral Wegovy (semaglutide) has demonstrated a 15% weight-loss average in clinical trials, while Foundayo (orforglipron) has helped people lose approximately 12% to 14% of their starting weight

On the negative side of things, the FDA updated the label for Ozempic with a warning about intestinal blockages after multiple reports of the rare but severe side effect

The "GLP-1" in the product name refers to the brand's marketing positioning around metabolic support rather than indicating the presence of pharmaceutical GLP-1 ingredients

The precise contribution of GIP receptor activation to weight reduction remains an area of active study

However, the proportion of IBS patients seeking clinical service in clinics is below 25% in China (Study Group of Functional Gastrointestinal Disorders et al., 2020)